Evofem Biosciences to Report Third Quarter 2021 Results and Provide Corporate Update on Monday, November 15, 2021

Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) will host a webcast and conference call on November 15, 2021, at 4:30 p.m. ET to discuss its third quarter 2021 financial results and business highlights. Investors can access the live and archived webcast through a link on their investor room page. Participation by phone is also available, and a replay will be provided for 24 hours after the call. Evofem focuses on women's sexual and reproductive health, with its primary product being Phexxi®, a hormone-free contraceptive gel.

SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the third quarter ended September 30, 2021 on Monday, November 15, 2021 at 4:30 p.m. ET (1:30 p.m. PT).

The webcast (live and archived) and related slide presentation can be accessed through https://evofem.investorroom.com/2021Q3Results or directly at https://edge.media-server.com/mmc/p/xmw874kh. Please connect to the webcast at least 15 minutes prior to the start of the call to download any software that may be required.

If participating by phone, please dial in approximately 15 minutes prior to the start of the call using (866) 503-5561 (U.S. toll-free) or (253) 336-2965, and referring to conference ID 7464495.

A telephone replay will be available for 24 hours after the call at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 7464495.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (chlamydia and gonorrhea). The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Phexxi^® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-report-third-quarter-2021-results-and-provide-corporate-update-on-monday-november-15-2021-301410776.html

SOURCE Evofem Biosciences, Inc.

FAQ

When will Evofem Biosciences report its Q3 2021 results?

Evofem Biosciences will report its Q3 2021 results on November 15, 2021.

What time is the Evofem Biosciences conference call?

The conference call will take place at 4:30 p.m. ET on November 15, 2021.

How can I access the Evofem Biosciences webcast?

The webcast can be accessed through Evofem's investor room page or directly from their website.

What is the conference ID for the Evofem Biosciences call?

The conference ID for the call is 7464495.

What product does Evofem Biosciences offer?

Evofem Biosciences offers Phexxi®, a hormone-free contraceptive vaginal gel.